Literature DB >> 26526537

Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?

Sam Gandy1, Mary Sano1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26526537      PMCID: PMC5959015          DOI: 10.1038/nrneurol.2015.218

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

Authors:  Yen Ying Lim; Paul Maruff; Robert H Pietrzak; David Ames; Kathryn A Ellis; Karra Harrington; Nicola T Lautenschlager; Cassandra Szoeke; Ralph N Martins; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  Brain       Date:  2013-10-30       Impact factor: 13.501

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Authors:  Michael Schöll; Anders Wall; Steinunn Thordardottir; Daniel Ferreira; Nenad Bogdanovic; Bengt Långström; Ove Almkvist; Caroline Graff; Agneta Nordberg
Journal:  Neurology       Date:  2012-06-13       Impact factor: 9.910

4.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Authors:  Willemijn J Jansen; Rik Ossenkoppele; Dirk L Knol; Betty M Tijms; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Pauline Aalten; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kristen Bibeau; Kaj Blennow; David J Brooks; Mark A van Buchem; Vincent Camus; Enrica Cavedo; Kewei Chen; Gael Chetelat; Ann D Cohen; Alexander Drzezga; Sebastiaan Engelborghs; Anne M Fagan; Tormod Fladby; Adam S Fleisher; Wiesje M van der Flier; Lisa Ford; Stefan Förster; Juan Fortea; Nadia Foskett; Kristian S Frederiksen; Yvonne Freund-Levi; Giovanni B Frisoni; Lutz Froelich; Tomasz Gabryelewicz; Kiran Dip Gill; Olymbia Gkatzima; Estrella Gómez-Tortosa; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Helmut Hildebrandt; Lianna Ishihara; Adrian Ivanoiu; William J Jagust; Peter Johannsen; Ramesh Kandimalla; Elisabeth Kapaki; Aleksandra Klimkowicz-Mrowiec; William E Klunk; Sebastian Köhler; Norman Koglin; Johannes Kornhuber; Milica G Kramberger; Koen Van Laere; Susan M Landau; Dong Young Lee; Mony de Leon; Viviana Lisetti; Alberto Lleó; Karine Madsen; Wolfgang Maier; Jan Marcusson; Niklas Mattsson; Alexandre de Mendonça; Olga Meulenbroek; Philipp T Meyer; Mark A Mintun; Vincent Mok; José Luis Molinuevo; Hanne M Møllergård; John C Morris; Barbara Mroczko; Stefan Van der Mussele; Duk L Na; Andrew Newberg; Agneta Nordberg; Arto Nordlund; Gerald P Novak; George P Paraskevas; Lucilla Parnetti; Gayan Perera; Oliver Peters; Julius Popp; Sudesh Prabhakar; Gil D Rabinovici; Inez H G B Ramakers; Lorena Rami; Catarina Resende de Oliveira; Juha O Rinne; Karen M Rodrigue; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Christopher C Rowe; Eckart Rüther; Osama Sabri; Páscual Sanchez-Juan; Isabel Santana; Marie Sarazin; Johannes Schröder; Christin Schütte; Sang W Seo; Femke Soetewey; Hilkka Soininen; Luiza Spiru; Hanne Struyfs; Charlotte E Teunissen; Magda Tsolaki; Rik Vandenberghe; Marcel M Verbeek; Victor L Villemagne; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Anders Wallin; Åsa K Wallin; Jens Wiltfang; David A Wolk; Marzena Zboch; Henrik Zetterberg
Journal:  JAMA       Date:  2015-05-19       Impact factor: 56.272

5.  Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Authors:  Enchi Liu; Mark E Schmidt; Richard Margolin; Reisa Sperling; Robert Koeppe; Neale S Mason; William E Klunk; Chester A Mathis; Stephen Salloway; Nick C Fox; Derek L Hill; Andrea S Les; Peter Collins; Keith M Gregg; Jianing Di; Yuan Lu; I Cristina Tudor; Bradley T Wyman; Kevin Booth; Stephanie Broome; Eric Yuen; Michael Grundman; H Robert Brashear
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

6.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

Authors:  Eric R Siemers; Karen L Sundell; Christopher Carlson; Michael Case; Gopalan Sethuraman; Hong Liu-Seifert; Sherie A Dowsett; Michael J Pontecorvo; Robert A Dean; Ronald Demattos
Journal:  Alzheimers Dement       Date:  2015-08-01       Impact factor: 21.566

7.  GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

Authors:  Vijay K Ramanan; Shannon L Risacher; Kwangsik Nho; Sungeun Kim; Li Shen; Brenna C McDonald; Karmen K Yoder; Gary D Hutchins; John D West; Eileen F Tallman; Sujuan Gao; Tatiana M Foroud; Martin R Farlow; Philip L De Jager; David A Bennett; Paul S Aisen; Ronald C Petersen; Clifford R Jack; Arthur W Toga; Robert C Green; William J Jagust; Michael W Weiner; Andrew J Saykin
Journal:  Brain       Date:  2015-08-11       Impact factor: 13.501

8.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; David S Knopman; Val Lowe; Prashanthi Vemuri; Michelle M Mielke; David T Jones; Matthew L Senjem; Jeffrey L Gunter; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen
Journal:  Neurology       Date:  2013-10-16       Impact factor: 9.910

9.  The A4 study: stopping AD before symptoms begin?

Authors:  Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

10.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.

Authors:  J C Lambert; C A Ibrahim-Verbaas; D Harold; A C Naj; R Sims; C Bellenguez; A L DeStafano; J C Bis; G W Beecham; B Grenier-Boley; G Russo; T A Thorton-Wells; N Jones; A V Smith; V Chouraki; C Thomas; M A Ikram; D Zelenika; B N Vardarajan; Y Kamatani; C F Lin; A Gerrish; H Schmidt; B Kunkle; M L Dunstan; A Ruiz; M T Bihoreau; S H Choi; C Reitz; F Pasquier; C Cruchaga; D Craig; N Amin; C Berr; O L Lopez; P L De Jager; V Deramecourt; J A Johnston; D Evans; S Lovestone; L Letenneur; F J Morón; D C Rubinsztein; G Eiriksdottir; K Sleegers; A M Goate; N Fiévet; M W Huentelman; M Gill; K Brown; M I Kamboh; L Keller; P Barberger-Gateau; B McGuiness; E B Larson; R Green; A J Myers; C Dufouil; S Todd; D Wallon; S Love; E Rogaeva; J Gallacher; P St George-Hyslop; J Clarimon; A Lleo; A Bayer; D W Tsuang; L Yu; M Tsolaki; P Bossù; G Spalletta; P Proitsi; J Collinge; S Sorbi; F Sanchez-Garcia; N C Fox; J Hardy; M C Deniz Naranjo; P Bosco; R Clarke; C Brayne; D Galimberti; M Mancuso; F Matthews; S Moebus; P Mecocci; M Del Zompo; W Maier; H Hampel; A Pilotto; M Bullido; F Panza; P Caffarra; B Nacmias; J R Gilbert; M Mayhaus; L Lannefelt; H Hakonarson; S Pichler; M M Carrasquillo; M Ingelsson; D Beekly; V Alvarez; F Zou; O Valladares; S G Younkin; E Coto; K L Hamilton-Nelson; W Gu; C Razquin; P Pastor; I Mateo; M J Owen; K M Faber; P V Jonsson; O Combarros; M C O'Donovan; L B Cantwell; H Soininen; D Blacker; S Mead; T H Mosley; D A Bennett; T B Harris; L Fratiglioni; C Holmes; R F de Bruijn; P Passmore; T J Montine; K Bettens; J I Rotter; A Brice; K Morgan; T M Foroud; W A Kukull; D Hannequin; J F Powell; M A Nalls; K Ritchie; K L Lunetta; J S Kauwe; E Boerwinkle; M Riemenschneider; M Boada; M Hiltuenen; E R Martin; R Schmidt; D Rujescu; L S Wang; J F Dartigues; R Mayeux; C Tzourio; A Hofman; M M Nöthen; C Graff; B M Psaty; L Jones; J L Haines; P A Holmans; M Lathrop; M A Pericak-Vance; L J Launer; L A Farrer; C M van Duijn; C Van Broeckhoven; V Moskvina; S Seshadri; J Williams; G D Schellenberg; P Amouyel
Journal:  Nat Genet       Date:  2013-10-27       Impact factor: 38.330

  10 in total
  5 in total

Review 1.  Alzheimer's disease hypothesis and related therapies.

Authors:  Xiaoguang Du; Xinyi Wang; Meiyu Geng
Journal:  Transl Neurodegener       Date:  2018-01-30       Impact factor: 8.014

Review 2.  The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.

Authors:  Munvar Miya Shaik; Ian A Tamargo; Murtala B Abubakar; Mohammad A Kamal; Nigel H Greig; Siew Hua Gan
Journal:  Genes (Basel)       Date:  2018-03-21       Impact factor: 4.096

Review 3.  New treatment modalities in Alzheimer's disease.

Authors:  Emel Koseoglu
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

Review 4.  Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.

Authors:  Livia La Barbera; Emanuele Mauri; Marcello D'Amelio; Manuele Gori
Journal:  Front Neurosci       Date:  2022-08-04       Impact factor: 5.152

5.  Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.

Authors:  Elysse M Knight; Soong Ho Kim; Jessica C Kottwitz; Asa Hatami; Ricardo Albay; Akinobu Suzuki; Alex Lublin; Cristina M Alberini; William L Klein; Paul Szabo; Norman R Relkin; Michelle Ehrlich; Charles G Glabe; Sam Gandy; John W Steele
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.